ViiV Healthcare

Janssen R&D, Viiv Healthcare collaborate on maintenance treatment for HIV

Friday, June 13, 2014 01:08 PM

Janssen R&D Ireland has entered into a collaboration with ViiV Healthcare to develop and commercialize a new, single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT) and ViiV's Integrase Inhibitor dolutegravir (marketed as TIVICAY) as the sole active ingredients for the maintenance treatment of people living with human immunodeficiency virus (HIV). The companies will further investigate development of this drug combination for pediatric use.

More... »


GlaxoSmithKline invests in Africa

Wednesday, April 2, 2014 01:54 PM

GlaxoSmithKline has announced a series of new investments in sub-Saharan Africa designed to address pressing health needs and contribute to long-term business growth. GSK CEO Sir Andrew Wittyhasset out the company’s intent to partner with governments of African countries to help stimulate more research into chronic diseases, increase capacity by localizing medicines supply and strengthen healthcare infrastructure.

More... »


ideaPoint launches multi-sponsor portal

Thursday, January 2, 2014 10:35 AM

ideaPoint, a provider of partnering and collaboration systems for global enterprises, has announced the availability of a new portal providing a secure system for researchers to request access to anonymized, patient-level clinical trial data provided by sponsors (clinicalstudydatarequest.com). Study sponsors who have committed to provide data through the site currently include Boehringer Ingelheim, GlaxoSmithKline, Roche, Sanofi and ViiV Healthcare.

More... »

Medicines Patent Pool collaborates with ViiV Healthcare

Friday, March 1, 2013 12:39 PM

The Medicines Patent Pool (MPP) has launched a collaboration with ViiV Healthcare—a joint venture of GlaxoSmithKline, Pfizer and Shionogi—to facilitate greater availability of critically needed medicines for children living with HIV.

More... »

Shionogi, ViiV Healthcare to commercialize and develop integrase inhibitor portfolio

Tuesday, October 30, 2012 11:19 AM

ViiV Healthcare, a global specialist HIV company based in the U.K., and Shionogi, a Japanese research-driven pharmaceutical company, have entered into an agreement substantially revising their integrase inhibitor relationship.

More... »

Siemens partners with ViiV Healthcare and Tocagen

Thursday, February 9, 2012 08:12 AM

Siemens Healthcare Diagnostics has formed two new companion diagnostics partnerships with pharmaceutical companies ViiV Healthcare and Tocagen—marking a step for Siemens into the fast-growing segment of the in vitro diagnostics market.

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs